Vivani Medical, Inc. (VANI) Reports Q3 Net Loss of $7.3M, Cash of $15.5M
Vivani Medical (VANI) reported a Q3 2026 net loss of $7.3M, up from $6.5M in Q3 2025. Cash reserves declined to $15.5M from $20.8M in Q2 2026. The company awaits SLIM-1 trial results and Cortigent merger completion.
How this was made
The 30-second read
Why it matters
The disclosed loss and cash burn may pressure the stock, but upcoming catalysts could offset the downside.
Market read
Primary earnings disclosure for a micro‑cap biotech; new data likely to move the stock in after‑hours trading.
What to watch
Potential upside from the pending Cortigent merger and SLIM‑1 data could mitigate the negative earnings impact.
Background
Vivani Medical is a clinical‑stage biotech reporting its quarterly financials.
Ticker impact
Q3 2026 earnings disclosed a wider net loss of $7.3M and a cash decline to $15.5M, new primary financial data for the company.
likely downside as investors price in the larger loss and reduced cash runway
Earnings are the first public disclosure of these numbers; the loss widened and cash fell, which typically depresses a micro‑cap stock.
Market effects
May raise concerns for other clinical‑stage biotech firms facing cash constraints.
Limited to U.S. small‑cap biotech segment.
Low
Counterpoint
If the upcoming SLIM‑1 announcement exceeds expectations, the loss could be viewed as a short‑term pain for long‑term upside.
Key entities
- companyVivani Medical, Inc.
Clinical‑stage biotech reporting Q3 results.
